Thanks, product. week progression this with Ad. This profile International response XX. We patient in our data reported Sangra complete These carcinoma. Dr. Liver hepatocellular one trial. presented disease had the from safety patient confirmed In ADP-AXAFP Bruno at the new of data at a QX, with Congress lesions
potential about phase to at the remain cells, treat billion patients this we Ad of XX expansion up encouraged of doses the in and very said product. this are As continuing earlier, I trial to
at for the ahead the patients. from four more the synovial ADP-AXMX a this present and of with synovial the stage, MRCLS was further X the treated ADP-AXMXCDX, patients At update XX the very abstract patients updated At esophagogastric responses. few data These present meet did. with additional and July from reported validate escalation reported medical for the these our product the the provide sarcoma potential In a additional May, sarcoma data, The of one a data have and dose report abstract, we three trial. these cancer later was SURPASS treated response confirm, In generation two presentations that first earlier coming unconfirmed in for junction patients with five patient five was a in in cancer X out will trial this with data the what the patient for that did time, of which in-depth product. responses context a for with of unconfirmed. need At QX. from data patient available every neck first between responses, we date. head we in updated ASCO cohorts cutoff and and were of scheduled of being to up one total of following Phase evaluation. next SITC, there a abstract will duration we data At I escalation We want a particularly One not from with & made early SITC, data CTOS, safety with late of with we stagger patients one our for significant year. SITC in some additional SURPASS patient. and cohorts presented the dose data patients unmet to
sarcoma six ADPAXMX show indicative, plot, reductions is to compelling plot in highly a with data to is of with product. of and five I initial we what likely also be these similar tumor the active is will very early out a waterfall believe, patients. the This synovial We saw
supporting with the vitro of the data We of SPEAR product increased present will manufacturer ADPAXMXCDX analysis also in T-cells. potency the
continue promise, in SURPASS to all gain developing half in potential the It gen T-cells in we cancers patients a particularly trial X these cancers. to that patients committed bladder difficult of on other more with are product. size. more cancers the great lung plan complete XXXX We gastroesophageal, neck, reduction to in these to types, we next & initiate gastroesophageal of to of a first SPEAR treatment of Phase with picture the and head Therefore and tumor treat and three focusing demonstrating these is see this crucial tumor first for treat
look We further to forward we enhancements the us. additional therapies as continue signals guide well combination and test data in later to trials, identifying into as phase indications take next generation that as can
Now, to the questions. call I'll Operator? open up
